Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


29.04.2019

1 Ann Oncol
2 Ann Surg Oncol
2 Ann Thorac Surg
5 BMC Cancer
1 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Sci
1 Clin Cancer Res
2 Clin Lung Cancer
1 Clin Nucl Med
1 Eur Respir J
1 Int J Cancer
1 J Cancer Res Clin Oncol
1 J Thorac Cardiovasc Surg
3 J Thorac Oncol
1 JAMA Oncol
1 Lung Cancer
1 Mol Carcinog
3 Oncogene
2 Oncologist


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
    Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.
    Ann Oncol. 2019 Apr 24. pii: 5479461. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. REINERSMAN JM
    Better Survival After 4L Lymph Node Dissection for Early-Stage, Left-Sided, Non-small Cell Lung Cancer: Are We Debating a False Duality?
    Ann Surg Oncol. 2019 Apr 23. pii: 10.1245/s10434-019-07382.
    PubMed     Text format    

  3. ZHAO K, Wei S, Mei J, Guo C, et al
    Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance.
    Ann Surg Oncol. 2019 Apr 22. pii: 10.1245/s10434-019-07368.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  4. STOKES SM, Massarweh NN, Stringham J, Varghese TK Jr, et al
    Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2019 Apr 23. pii: S0003-4975(19)30572.
    PubMed     Text format     Abstract available

  5. NELSON DB, Mehran RJ, Mitchell KG, Rajaram R, et al
    Robotic Assisted Lobectomy For Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience.
    Ann Thorac Surg. 2019 Apr 17. pii: S0003-4975(19)30558.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. ABE M, Watanabe K, Shinozaki-Ushiku A, Ushiku T, et al
    Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.
    BMC Cancer. 2019;19:52.
    PubMed     Text format     Abstract available

  7. HABEL N, Stefanovska B, Carene D, Patino-Garcia A, et al
    CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rbeta-dependent EMT-like process.
    BMC Cancer. 2019;19:62.
    PubMed     Text format     Abstract available

  8. CONNOCK M, Armoiry X, Tsertsvadze A, Melendez-Torres GJ, et al
    Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and sec
    BMC Cancer. 2019;19:392.
    PubMed     Text format     Abstract available

  9. D'ALMEIDA PRETO D, Baston MT, Geraige CC, Augusto SB, et al
    Impact of AferBio(R) on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
    BMC Cancer. 2019;19:382.
    PubMed     Text format     Abstract available

  10. LI M, Li H, Hong G, Tang Z, et al
    Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    BMC Cancer. 2019;19:67.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  11. MISTRY HB, Helmlinger G, Al-Huniti N, Vishwanathan K, et al
    Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics.
    Cancer Chemother Pharmacol. 2019 Apr 24. pii: 10.1007/s00280-019-03840.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  12. HUO J, Hong YR, Bian J, Guo Y, et al
    Low Rates of Patient-Reported Physician-Patient Discussion about Lung Cancer Screening among Current Smokers: Data from Health Information National Trends Survey.
    Cancer Epidemiol Biomarkers Prev. 2019 Apr 25. pii: 1055-9965.EPI-18-0629.
    PubMed     Text format     Abstract available

  13. GRAFETSTATTER M, Husing A, Gonzalez Maldonado S, Sookthai D, et al
    Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study.
    Cancer Epidemiol Biomarkers Prev. 2019 Apr 23. pii: 1055-9965.EPI-18-1285.
    PubMed     Text format     Abstract available


    Cancer Sci

  14. ANDO A, Hashimoto N, Sakamoto K, Omote N, et al
    Repressive role of stabilized HIF1alpha expression on TGFbeta-induced extracellular matrix production in lung cancer cells.
    Cancer Sci. 2019 Apr 20. doi: 10.1111/cas.14027.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  15. XU Y, Hosny A, Zeleznik R, Parmar C, et al
    Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-2495.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  16. CHOI M, Keam B, Ock CY, Kim M, et al
    Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
    Clin Lung Cancer. 2019 Mar 29. pii: S1525-7304(19)30078.
    PubMed     Text format     Abstract available

  17. KOH Y, Yagi S, Akamatsu H, Kanai K, et al
    Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Clin Lung Cancer. 2019 Mar 25. pii: S1525-7304(19)30077.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  18. BEER L, Hochmair M, Haug AR, Schwabel B, et al
    Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
    Clin Nucl Med. 2019 Apr 19. doi: 10.1097/RLU.0000000000002603.
    PubMed     Text format     Abstract available


    Eur Respir J

  19. WIJMANS L, Yared J, de Bruin DM, Meijer SL, et al
    Needle-based confocal laser endomicroscopy (nCLE) for real-time diagnosing and staging of lung cancer.
    Eur Respir J. 2019 Apr 25. pii: 13993003.01520-2018.
    PubMed     Text format     Abstract available


    Int J Cancer

  20. QU J, Liu L, Xu Q, Ren J, et al
    CARD9 protects lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32355.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  21. ZHU J, Liu W, Chen C, Zhang H, et al
    TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells.
    J Cancer Res Clin Oncol. 2019 Apr 23. pii: 10.1007/s00432-019-02921.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  22. NELSON DB, Mehran RJ, Mitchell KG, Correa AM, et al
    Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Mar 21. pii: S0022-5223(19)30677.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  23. HUNG RJ, Spitz MR, Houlston RS, Schwartz AG, et al
    Lung Cancer Risk in Never Smokers of European Descent is Associated with Genetic Variation in the 5P15.33 TERT-CLPTM1L Region.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30289.
    PubMed     Text format     Abstract available

  24. DAI J, Liu M, Yang Y, Li Q, et al
    Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30290.
    PubMed     Text format     Abstract available

  25. JIN Y, Dong H, Xia L, Yang Y, et al
    The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30286.
    PubMed     Text format     Abstract available


    JAMA Oncol

  26. BERNER F, Bomze D, Diem S, Ali OH, et al
    Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Apr 25. pii: 2731134. doi: 10.1001/jamaoncol.2019.0402.
    PubMed     Text format     Abstract available


    Lung Cancer

  27. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lu
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30397.
    PubMed     Text format    


    Mol Carcinog

  28. SUN Q, Wang Y, Fan J, Li Z, et al
    Association of expression quantitative trait loci for long noncoding RNAs with lung cancer risk in Asians.
    Mol Carcinog. 2019 Apr 26. doi: 10.1002/mc.23013.
    PubMed     Text format     Abstract available


    Oncogene

  29. PATEL Y, Soni M, Awgulewitsch A, Kern MJ, et al
    Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
    Oncogene. 2019;38:445-453.
    PubMed     Text format     Abstract available

  30. HAN J, Wang F, Lan Y, Wang J, et al
    KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
    Oncogene. 2018 Aug 16. pii: 10.1038/s41388-018-0440.
    PubMed     Text format     Abstract available

  31. MA A, Tang M, Zhang L, Wang B, et al
    USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0590.
    PubMed     Text format     Abstract available


    Oncologist

  32. OTSUBO K, Sakai K, Takeshita M, Harada D, et al
    Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Oncologist. 2019 Apr 25. pii: theoncologist.2019-0101.
    PubMed     Text format     Abstract available

  33. PAVAN A, Calvetti L, Dal Maso A, Attili I, et al
    Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Oncologist. 2019 Apr 23. pii: theoncologist.2018-0563.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: